Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2012

Open Access 01-12-2012 | Research

Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study

Authors: Richard H Osborne, Andrew Dalton, Judy Hertel, Rudolf Schrover, Dell Kingsford Smith

Published in: Health and Quality of Life Outcomes | Issue 1/2012

Login to get access

Abstract

Background

This study was undertaken to estimate utility values for alternative treatment intervals for long acting antipsychotic intramuscular injections for the treatment of schizophrenia.

Methods

Vignettes were developed using the published literature and an iterative consultation process with expert clinicians and patient representative groups. Four vignettes were developed. The first was a vignette of relapsed/untreated schizophrenia. The other three vignettes presented a standardised picture of well-managed schizophrenia with variations in the intervals between injections: once every 2-weeks, 4-weeks and 3-months. A standardised time trade off (TTO) approach was used to obtain utility values for the vignettes. As a societal perspective was sought, a representative sample of individuals from across the community (Sydney, Australia) was recruited. Ninety-eight people completed the TTO interview. The vignettes were presented in random order to prevent possible ordering effects.

Results

A clear pattern of increasing utility was observed with increasing time between injections. Untreated schizophrenia was rated as very poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-monthly: mean (median) utility = 0.70 (0.75).

Conclusions

This study has provided robust data indicating that approximately a 0.05 utility difference exists between treatment options, with the highest utility assigned to 3-monthly injections.
Appendix
Available only for authorised users
Literature
1.
Association AP: Diagnostic and statistical manual of mental disorders: DSM-IV. 4th edition. Washington (DC): American Psychiatric Association; 1994.
2.
Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992, 20: 1–97.CrossRefPubMed
3.
McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D: A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2: 13. 10.1186/1741-7015-2-13PubMedCentralCrossRefPubMed
4.
Murray CJ, Lopez ADe: The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard University Press on behalf of the World Health Organization and the World Bank; 1996:990.
5.
Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ: Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003, 37(1):31–40. 10.1046/j.1440-1614.2003.01092.xCrossRefPubMed
6.
Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, et al.: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56(3):241–247. 10.1001/archpsyc.56.3.241CrossRefPubMed
7.
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM: Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176(2–3):109–113.
8.
Velligan DI, Lam F, Ereshefsky L, Miller AL: Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003, 54(5):665–667. 10.1176/appi.ps.54.5.665CrossRefPubMed
9.
Haddad PM, Taylor M, Niaz OS: First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009, 52: S20–28.CrossRefPubMed
10.
Johnson DA: Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl 2009, 52: S7–12.CrossRefPubMed
11.
Barnes TR, Shingleton-Smith A, Paton C: Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009, 52: S37–42.CrossRefPubMed
12.
Kulkarni J, Dalton A, Katz P, et al.: A survey to assess pain associated with routine administration of intramuscular risperidone long-acting injection. Australian Society for Psychiatric Research (ASPR): Bondi, Sydney; 2010.
13.
Osborne RH, De Abreu Lourenco R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ: Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007, 10(6):451–456. 10.1111/j.1524-4733.2007.00200.xCrossRefPubMed
14.
Dolan P: Output measures and valuation in health. Oxford: Oxford University Press; 2001.
15.
Torrance GW: Utility measurement in healthcare: the things I never got to. Pharmacoeconomics 2006, 24(11):1069–1078. 10.2165/00019053-200624110-00004CrossRefPubMed
16.
Australian Bureau of Statistics: Population by Age and Sex, Australian States and Territories. Canberra: Australian Bureau of Statistics; 2009.
17.
Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD: A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res 2005, 40(2):577–591. 10.1111/j.1475-6773.2005.0l374.xPubMedCentralCrossRefPubMed
18.
Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008, 6: 105. 10.1186/1477-7525-6-105PubMedCentralCrossRefPubMed
19.
Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lubbert M, Deschler B, Fenaux P, Mufti GJ, Killick S, et al.: Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes 2009, 7: 81. 10.1186/1477-7525-7-81PubMedCentralCrossRefPubMed
20.
Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S: Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000, 320(7231):341–346. 10.1136/bmj.320.7231.341PubMedCentralCrossRefPubMed
21.
Nease RF Jr, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D, Sox HC: Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995, 273(15):1185–1190. 10.1001/jama.1995.03520390045031CrossRefPubMed
22.
Froberg DG, Kane RL: Methodology for measuring health-state preferences-II: Scaling methods. J Clin Epidemiol 1989, 42(5):459–471. 10.1016/0895-4356(89)90136-4CrossRefPubMed
23.
Barber MN, Staples M, Osborne RH, Clerehan R, Elder C, Buchbinder R: Up to a quarter of the Australian population may have suboptimal health literacy depending upon the measurement tool: results from a population-based survey. Health Promot Int 2009, 24(3):252–261. 10.1093/heapro/dap022CrossRefPubMed
Metadata
Title
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study
Authors
Richard H Osborne
Andrew Dalton
Judy Hertel
Rudolf Schrover
Dell Kingsford Smith
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2012
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-10-35

Other articles of this Issue 1/2012

Health and Quality of Life Outcomes 1/2012 Go to the issue

Research

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china

Research

The Achilles tendon total rupture score: a study of responsiveness, internal consistency and convergent validity on patients with acute Achilles tendon ruptures

Research

Comparison of the OHIP-14 and GOHAI as measures of oral health among elderly in Lebanon

Research

Prevalence and impacts of poor sleep on quality of life and associated factors of good sleepers in a sample of older Chinese adults

Research

Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study

Research

Quality of life of caregivers with relatives suffering from mental illness in Hong Kong: roles of caregiver characteristics, caregiving burdens, and satisfaction with psychiatric services